Literature DB >> 26837734

New Insights into the Epithelial-to-Mesenchymal Transition in Cancer.

Xiaolong Qi1, Li Zhang2, Xiaojie Lu3.   

Abstract

The role of the epithelial-to-mesenchymal transition (EMT) in cancer progression is a long-debated issue. Recent evidence shows that EMT is not a prerequisite for cancer metastasis, but does confer chemoresistance. Future studies are needed to profile EMT events in different cancer types and under different circumstances to explore their potentials as therapeutic targets.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer metastasis; chemoresistance; epithelial-to-mesenchymal transition

Mesh：

Year:  2016        PMID： 26837734     DOI： 10.1016/j.tips.2016.01.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  15 in total

Review 1.  The emerging role of circular RNAs in gastric cancer.

Authors:  Peina Shi; Jiangnan Wan; Haojun Song; Xiaoyun Ding
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

2.  FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.

Authors:  Jinfeng Zhu; Jiefeng Zhao; Chen Luo; Zhengming Zhu; Xingyu Peng; Xiaojian Zhu; Kang Lin; Fanqin Bu; Wenjun Zhang; Qing Li; Kai Wang; Zhigang Hu; Xin Yu; Leifeng Chen; Rongfa Yuan
Journal:  Cell Death Dis       Date:  2022-05-25       Impact factor: 9.685

3.  Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.

Authors:  Jun Huang; Yongzhao Zhao; Yong Xu; Yanjie Zhu; Jiale Huang; Yanna Liu; Liying Zhao; Zhijia Li; Hao Liu; Qi-Long Wang; Xiaolong Qi
Journal:  Oncotarget       Date:  2016-06-07

4.  Pinin facilitated proliferation and metastasis of colorectal cancer through activating EGFR/ERK signaling pathway.

Authors:  Zhigang Wei; Wenhui Ma; Xiaolong Qi; Xianjun Zhu; Yutian Wang; Zhuoluo Xu; Jun Luo; Da Wang; Weihong Guo; Xiaomei Li; Sainan Xin; Jiang Yu; Guoxin Li
Journal:  Oncotarget       Date:  2016-05-17

5.  CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630.

Authors:  Yan Zhang; Hao Liu; Wende Li; Jiang Yu; Jin Li; Zhiyong Shen; Gentai Ye; Xiaolong Qi; Guoxin Li
Journal:  Aging (Albany NY)       Date:  2017-06-27       Impact factor: 5.682

6.  Circular RNAs signature predicts the early recurrence of stage III gastric cancer after radical surgery.

Authors:  Yan Zhang; Jin Li; Jiang Yu; Hao Liu; Zhiyong Shen; Gentai Ye; Tingyu Mou; Xiaolong Qi; Guoxin Li
Journal:  Oncotarget       Date:  2017-04-04

7.  S100A4-MYH9 Axis Promote Migration and Invasion of Gastric Cancer Cells by Inducing TGF-β-Mediated Epithelial-Mesenchymal Transition.

Authors:  Fengping Li; Jiaolong Shi; Zhijun Xu; Xingxing Yao; Tingyu Mou; Jiang Yu; Hao Liu; Guoxin Li
Journal:  J Cancer       Date:  2018-10-05       Impact factor: 4.207

8.  MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.

Authors:  Qianqian Yu; Yiqian Liu; Chengcai Wen; Yongzhao Zhao; Shidai Jin; Youfang Hu; Feng Wang; Liang Chen; Bin Zhang; Wei Wang; Quan Zhu; Renhua Guo
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

9.  Circ-104916 is downregulated in gastric cancer and suppresses migration and invasion of gastric cancer cells.

Authors:  Jin Li; Li Zhen; Yan Zhang; Liying Zhao; Hao Liu; Danxian Cai; Hao Chen; Jiang Yu; Xiaolong Qi; Guoxin Li
Journal:  Onco Targets Ther       Date:  2017-07-17       Impact factor: 4.147

10.  PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.

Authors:  Olga Karicheva; José Manuel Rodriguez-Vargas; Nadège Wadier; Kathline Martin-Hernandez; Romain Vauchelles; Najat Magroun; Agnès Tissier; Valérie Schreiber; Françoise Dantzer
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.